Advertisement
Clinical Trials
Subscribe to Clinical Trials
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Apple's ResearchKit - The Real Impact on Clinical Trials

May 1, 2015 11:57 am | by Merrilyn Datta, Ph.D., President and General Manager, Definiens | Articles | Comments

Apple recently released news about its new ResearchKit, a medical platform that intends to turn the iPhone and HealthKit into diagnostic tools. The technology, which enables researchers to create apps that gather new types of health data from users who opt-in, has gotten quite a bit of attention throughout the healthcare and technology communities. Read more...

Bayer's Contraception Safe, Effective: 5-Year Follow-Up Study

May 1, 2015 11:42 am | News | Comments

Bayer HealthCare announced today that a study published online this week in The Journal of Minimally Invasive Gynecology reinforces findings from previous clinical studies that support the effectiveness and safety of the Essure inserts and procedure for hysteroscopic sterilization, or permanent birth control. Read more...

The Prospect of Drugs to Treat Gluten Sensitivity

April 30, 2015 1:31 pm | by Stephanie Guzowski, Editor | News | Comments

Pharmaceutical companies are working to develop treatments as a first line of defense against gluten-sensitive symptoms — including abdominal pain, bloating, diarrhea, headaches and fatigue. Read more...

Advertisement

3 Ways Technology is Changing the Face of Drug Discovery & Development

April 29, 2015 9:04 am | by Merrilyn Datta, PhD, President and General Manager, Definiens | Articles | Comments

While personalized medicine has been a goal for some time, there have been several obstacles. Although there has been an explosion in genomic data, the corresponding clinical utility for this data has been slow to be validated. Read more...

Novartis Announces Phase 3 Study of CLL Drug Met Primary Endpoint

April 28, 2015 4:34 pm | News | Comments

The safety profile observed in this trial is consistent with other trials of Arzerra and no new safety signals were observed. Read more....

GSK Shingles Vaccine Demonstrates 97.2% Efficacy in Phase 3 Study

April 28, 2015 8:37 am | News | Comments

GlaxoSmithKline presented detailed data from a randomized phase 3 study of its investigational vaccine candidate for the prevention of shingles. Read more...

MedDay Reports Positive Phase 3 Results from MS Drug Study

April 27, 2015 8:37 am | News | Comments

The study demonstrated evidence of the efficacy and safety of MD1003, a highly-concentrated pharmaceutical-grade biotin administered at a dose of 300 mg per day in the treatment of primary and secondary progressive multiple sclerosis, a major area of unmet medical need. Read more....

Bristol-Myers Gets Positive EMA Opinion for Immunotherapy Drug, Opdivo

April 24, 2015 12:36 pm | by Stephanie Guzowski, Editor | Articles | Comments

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Bristol-Myers Squibb’s Opdivo today for the treatment of melanoma. Read more..

Advertisement

Human Clinical Trials Planned for New Anti-Cancer Compound

April 23, 2015 8:55 am | by University of Auckland | News | Comments

Researchers developed a new anti-cancer compound that will advance to human phase two clinical trials. Read more...

AACR 2015: Pembrolizumab Comes Out on Top for Melanoma, Lung Cancer

April 22, 2015 10:33 am | by Stephanie Guzowski, Editor | Articles | Comments

At the AACR Annual Meeting 2015, immunotherapies, called PD-1 inhibitors, were front and center stage, due to clinical trial results that led to U.S. Food and Drug Administration (FDA) approvals for treating melanoma and non-small cell lung cancer (NSCLC). Read more..

GW Pharmaceuticals Initiates Second Phase 3 Trial for Epidiolex

April 21, 2015 3:15 pm | News | Comments

This drug is intended for the treatment of Dravet syndrome. Read more...

Isarna Initiates First-in-Human Phase I Trial for Drug to Treat Advanced Glaucoma

April 17, 2015 8:11 am | News | Comments

The trial will enroll approximately 24 - 30 patients. Read more...

Pfizer Breast Cancer Drug Shows Promising Results

April 16, 2015 2:19 pm | by Stephanie Guzowski, Editor | News | Comments

Pfizer said on Wednesday a late-stage trial of its treatment for advanced breast cancer, Ibrance, was stopped early after it met its primary goal of delaying disease progression. Read more...

Advertisement

A Patch for Peanut Allergies

April 9, 2015 11:56 am | by Bevin Fletcher, Associate Editor | News | Comments

French biopharmaceutical company DBV Technologies moves closer to bringing its peanut allergy patch to market, receiving Breakthrough Therapy Designation from the U.S. Food and Drug Administration as it prepares to launch its Phase 3 trial. Read more...

Risk of Breast, Ovarian Cancer May Differ By Type of BRCA1, BRCA2 Mutation: Study

April 8, 2015 12:51 pm | by UPenn | News | Comments

In a study involving more than 31,000 women with cancer-causing mutations in the BRCA1 or BRCA2 genes, researchers at the Basser Center for BRCA, the Abramson Cancer Center, and the Perelman School of Medicine at the University of Pennsylvania, identified mutations that are associated with significantly different risks of breast and ovarian cancers. Read more...

Personalized Melanoma Vaccines Marshal Immune Response

April 6, 2015 9:49 am | by Washington University in St. Louis | News | Comments

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients’ tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis. Read more...

Experimental Ebola Vaccine Appears Safe, Prompts Immune Response

April 2, 2015 10:35 am | by NIH | News | Comments

An early-stage clinical trial of an experimental Ebola vaccine conducted at the National Institutes of Health (NIH) and the Walter Reed Army Institute of Research (WRAIR) found that the vaccine, called VSV-ZEBOV, was safe and elicited robust antibody responses in all 40 of the healthy adults who received it. Read more...

GeoVax HIV Vaccine Moves Forward

April 1, 2015 1:40 pm | News | Comments

GeoVax Labs, a biotechnology company developing human vaccines for Ebola and HIV, today announced that the HIV Vaccine Trials Network (HVTN) has assigned a trial number, HVTN 114, to the next clinical trial of its clade B preventive HIV vaccine candidate. Read more...

BioDelivery Sciences’ Pain Treatment Fails Study

March 30, 2015 3:46 pm | by Stephanie Guzowski, Editor | News | Comments

BioDelivery Sciences International Inc. said on Monday its pain drug for diabetic neuropathy failed to meet the primary goal in a Phase 3 clinical trial. Shares fell nearly 30 percent. Read more...

Integrative Approaches Key to Understanding Cancer and Developing Therapies

March 29, 2015 3:16 pm | by Moffitt Cancer Center | News | Comments

Researchers are using integrative approaches to study cancer by combining mathematical and computational modeling with experimental and clinical data. Read more...

Roseroot Shows Promise as Potential Depression Treatment Option

March 27, 2015 10:27 am | by Penn University | News | Comments

Rhodiola rosea (R. rosea), or roseroot, may be a beneficial treatment option for major depressive disorder (MDD), according to results of a study in the journal Phytomedicine. Read more...

HIV Replicates in Brain Earlier than Thought: Study

March 26, 2015 2:05 pm | by Stephanie Guzowski, Editor | News | Comments

A recent study, funded by the National Institutes of Health (NIH), highlights the importance of HIV screening and beginning antiretroviral therapy (ART) as early as possible. The analysis of cerebral spinal fluid (CSF), which illuminates brain chemical activity, showed that HIV can begin replicating in a patient’s brain as early as four months after infection. Read more...

Men’s Heart Disease Partly Due to Low Estrogen

March 26, 2015 8:52 am | by Cynthia Fox, Science Writer | Articles | Comments

One reason men have more heart disease than women is the very fact that they are men, reports Harvard University endocrinologist Evelyn Yu, M.D., MS.c. Both men’s higher testosterone levels and their lower estrogen levels, play a role. Read more...

Sanofi Announces Top-Line Results for Study of Lyxumia

March 19, 2015 4:32 pm | News | Comments

Full results will be presented at the American Diabetes Association 75th Scientific Sessions in Boston. Read more...

World-First Cancer Drugs Could Work in Larger Group of Patients

March 19, 2015 4:22 pm | by Institute of Cancer Research | News | Comments

A pioneering class of drugs that target cancers with mutations in the BRCA breast cancer genes could also work against tumors with another type of genetic fault. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading